Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 5/20 | 0.40 |
| ▸ | GPR3 | P46089 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22315067 | 0.88 | CXCR2 (0.35) | CXCR2LIPEGPR3SCN5ACYP1A2 | |
| SCHEMBL30376702 | 0.85 | CXCR2 (0.43) | CXCR2LIPEGPR3CA1CA2 | |
| SCHEMBL581309 | 0.85 | CXCR2 (0.43) | CXCR2LIPEGPR3CA1CA2 | |
| SCHEMBL28961843 | 0.84 | CXCR2 (0.42) | CXCR2LIPEGPR3CA1CA2 | |
| SCHEMBL31114631 | 0.84 | CXCR2 (0.42) | CXCR2LIPEGPR3CA1CA2 | |
| SCHEMBL30080384 | 0.82 | CXCR2 (0.39) | CXCR2LIPEGPR3UCHL1 | |
| SCHEMBL25436535 | 0.82 | LMNA (0.36) | CXCR2LIPECA1CA2CA9 | |
| SCHEMBL16798730 | 0.82 | LIPE (0.40) | CXCR2LIPEGPR3CA1CA2 | |
| SCHEMBL19025819 | 0.81 | LIPE (0.39) | CXCR2LIPEGPR3CYP1A2 | |
| SCHEMBL13202141 | 0.81 | CXCR2 (0.49) | CXCR2LIPEGPR3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479844-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3548033-B1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11918571-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11773099-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773099-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2020-06-11 | — | — | US | disclosed |
| WO-2020069322-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| CN-110337295-A | Compounds and methods of their use | 普拉克西斯精密药物股份有限公司 | 2019-10-15 | — | — | CN | disclosed |
| EP-3548033-A1 | COMPOUNDS AND THEIR METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019035951-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018148745-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES , INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918571-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN2A | CXCR2 4028/4885LIPE 4032/4885GPR3 1391/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CXCR2 3728/4885LIPE 4076/4885GPR3 1830/4885 |
| US-11773099-B2 | Compounds and their methods of use | SCN1A, SCN1B, SCN3A | CXCR2 2140/4885LIPE 4305/4885GPR3 1341/4885 |
| US-12479844-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | CXCR2 4447/4885LIPE 4223/4885GPR3 722/4885 |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN2A | CXCR2 4028/4885LIPE 4032/4885GPR3 1391/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CXCR2 3728/4885LIPE 4076/4885GPR3 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.